Objective - to study the efficiency of combination therapy using the immunomodulator polyoxydonium in women with chronic recurrent cystitis in the presence of urogenital infection. Subject and methods. Eighty-five women with chronic recurrent cystitis (a study group) were examined; clinic-anamnestic data, laboratory and instrumental findings and immune status were studied; combination treatment involving the immunomodulator polyoxydonium was performed. A control group consisted of 74 women without urogenital pathology. Results. Polymerase chain reaction (PCR) revealed that cervical canal specimens from the women with chronic cystitis contained U. urealyticum and M. hominis in 16.5 and 7.1% of cases, as well as the associations of U. urealyticum + M. hominis + Ch. trachomatis and U. urealyticum + Tr. vaginalis in 42.3 and 21.2%, respectively. Cultures of bladder mucosal biopsy specimens showed monoinfection in 29.6% and microbial associations in 70.4%. Prior to treatment, there had been suppression cell-mediated immunity, impaired T-lymphocyte subpopulation composition, imbalanced immunoglobulins, and inhibited phagocytic activity. Following treatment, 95.5% of the women reported no complaints of pain of different locations; dysuric symptoms were relieved in 85.9%. The data of PCR and bladder mucosal biopsy cultures showed that the pathogens were eliminated in 97.6 and 98.8% of the women, respectively. There were increased T and B cell counts, IgG and IgA recovery, and phagocytosis activation. Conclusion. Thus, combined pharmacotherapy using the immunomodulator polyoxydonium contributes to the recovery of immune homeostasis and indirectly affects the elimination of urogenital pathogens and the reduction of the clinical manifestations of chronic recurrent cystitis in women.